Professor Bosnic-Anticevich is a respiratory research pharmacist and is founder and Head of the Quality Use of Respiratory Medicines Group at the Woolcock Institute of Medical Research and The University of Sydney. Sinthia’s group focuses on the use of respiratory medicines in different patient populations, across the continuum of health care settings, with a multi-dimensional and inter-professional approach to improving health outcomes for patients using respiratory medicines. The research of Sinthia and her group has changed the landscape of inhaler technique research; impacting on national and international treatment guidelines. Sinthia is the author of over 160 research publications and has attracted over $17 million of research funding in the field of respiratory medicines and medicines use. She is actively involved in the mentoring and supervision of research students and early career researchers. Sinthia is President of the Respiratory Effectiveness Group (REG); a global, investigator-led, not-for-profit research initiative, built on a network of over 300 researchers, focused on real-life research, which produces research output and harnesses real-life evidence which informs meaningful practice guidelines, drug licensing and prescribing decision. She is on the executive of ARIA (Allergic Rhinitis in Asthma), Chair of Pharmacy ARIA and Chair of the Primary Care SIG of the Thoracic Society of Australia and New Zealand. Sinthia is on the Editorial Board of several prestigious international respiratory journals, including the European Respiratory, European Respiratory Journal Monograph and The Medical Republic (Australia’s most widely circulated GP newsletter). Sinthia sits on several global advisory boards for the pharmaceutical industry, associated with the use of medicines in the management of respiratory diseases.